Education
About Us
Working with TipRanks
Follow Us
BioLineRX Ltd. (IL:BLRX)
:BLRX
BLRX Stock Chart & Stats
1.50
>-0.01(-6.00%)
At close: 4:00 PM EST
1.50
>-0.01(-6.00%)
Day’s Range― - ―
52-Week Range1.40 - 3.90
Previous CloseN/A
Volume20.50M
Average Volume (3M)4.64M
Market Cap
₪39.16M
Enterprise Value15.97M
Total Cash (Recent Filing)₪25.21M
Total Debt (Recent Filing)₪11.38M
Price to Earnings (P/E)―
Beta0.52
Next Earnings
May 27, 2026EPS EstimateN/A
Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)N/A
Shares Outstanding2,610,814,500
10 Day Avg. Volume5,813,402
30 Day Avg. Volume4,637,561
Financial Highlights & Ratios
PEG Ratio0.03
Price to Book (P/B)1.59
Price to Sales (P/S)0.74
P/FCF Ratio-0.49
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price TargetN/A
Price Target UpsideN/A
Rating ConsensusN/A
Number of Analyst Covering0
EPS Forecast (FY)>-0.01
Revenue Forecast (FY)₪2.14M
Bulls Say, Bears Say
Bulls Say
Strategic JV For GLIX1The JV with Hemispherian gives Bioline Rx access to complementary scientific expertise and shared development risk for GLIX1. Holding an initial 40% stake (with potential to rise) and a planned Phase I/IIa trial provides durable optionality and de‑risking versus sole internal development.
Patent Protection For GLIX1A granted patent extending protection into 2040 creates a long‑lived exclusivity window for GLIX1, supporting long‑term commercial returns and partnership value. Broad use/combo claims strengthen competitive barriers and improve leverage in licensing or royalty arrangements.
Cash Runway And Recurring RoyaltiesA multi‑quarter cash runway reduces near‑term financing pressure, enabling execution of planned trials and JV contributions without immediate capital raises. Existing royalty inflows validate commercial partnerships and provide recurring, non‑dilutive liquidity to support development.
Bears Say
Negative Operating Cash FlowPersistent negative operating cash flow and falling free cash flow indicate the company cannot internally fund growth. This creates ongoing dependence on financing, milestones or partners, raising dilution and execution risk for multi‑trial advancement over the next 2–6 months.
Rising Leverage & Negative ROEHigher leverage and continued negative ROE reduce financial flexibility and increase fixed obligations. This combination constrains the firm’s ability to invest in R&D or absorb trial setbacks without costly financing, weakening balance sheet resilience over the medium term.
Reduced R&D And Commercial CapabilityMaterial cuts to R&D and elimination of sales/marketing reflect a smaller internal development and commercialization footprint. While lowering burn, this also reduces pipeline breadth and internal launch capability, increasing reliance on partners and limiting upside from proprietary commercialization.
Bioline Rx News
BLRX FAQ
What was BioLineRX Ltd.’s price range in the past 12 months?
BioLineRX Ltd. lowest stock price was 1.40 and its highest was 3.90 in the past 12 months.
What is BioLineRX Ltd.’s market cap?
BioLineRX Ltd.’s market cap is ₪39.16M.
When is BioLineRX Ltd.’s upcoming earnings report date?
BioLineRX Ltd.’s upcoming earnings report date is May 27, 2026 which is in 72 days.
How were BioLineRX Ltd.’s earnings last quarter?
Currently, no data Available
Is BioLineRX Ltd. overvalued?
According to Wall Street analysts BioLineRX Ltd.’s price is currently Overvalued.
Does BioLineRX Ltd. pay dividends?
BioLineRX Ltd. does not currently pay dividends.
What is BioLineRX Ltd.’s EPS estimate?
BioLineRX Ltd.’s EPS estimate for its next earnings report is not yet available.
How many shares outstanding does BioLineRX Ltd. have?
BioLineRX Ltd. has 2,610,814,500 shares outstanding.
What happened to BioLineRX Ltd.’s price movement after its last earnings report?
Currently, no data Available
Which hedge fund is a major shareholder of BioLineRX Ltd.?
Currently, no hedge funds are holding shares in IL:BLRX
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Company Description
BioLineRX Ltd.
BioLineRx Ltd., a clinical-stage biopharmaceutical development company, focuses on oncology. The company develops Motixafortide, a peptide, which has completed Phase 3 clinical trials for the treatment of autologous stem cell mobilization and Phase 2a clinical trials for the treatment of pancreatic cancer; and that is in Phase 2 clinical trials for the treatment of metastatic pancreatic adenocarcinoma patients, and Phase 1b clinical trials in patients with acute respiratory distress syndrome secondary to COVID-19 and other respiratory viral infections, as well as for the treatment of solid tumors and acute myeloid leukemia. It is also developing AGI-134, an immuno-oncology agent, which is in Phase 1/2a clinical trials for the treatment of solid tumors; and BL-5010, a customized, proprietary, pen-like applicator for the non-surgical removal of skin lesions. The company has collaboration agreement with MSD for the cancer immunotherapy field; MD Anderson Cancer Center to investigate the combination of Motixafortide with KEYTRUDA (pembrolizumab) in pancreatic cancer; and licensing arrangement with Perrigo Company plc for over-the-counter sale of BL-5010. BioLineRx Ltd. was incorporated in 2003 and is headquartered in Hevel Modi'in, Israel.